Aetion and McKesson Collaborate on RWE Cancer Research

October 16, 2019

Pharmaceutical Executive

Aetion-a healthcare technology company that delivers real-world evidence (RWE) for life sciences companies, payers, at-risk providers, and regulatory agencies-and McKesson announced a strategic collaboration focused on advancing the use of RWE in cancer research to benefit patients, regulators, the biopharma industry, and payers. The partnership will provide solutions in multiple tumor types, including breast, lung, and melanoma cancers.

Aetion-a healthcare technology company that delivers real-world evidence (RWE) for life sciences companies, payers, at-risk providers, and regulatory agencies-and McKesson announced a strategic collaboration focused on advancing the use of RWE in cancer research to benefit patients, regulators, the biopharma industry, and payers. The partnership will provide solutions in multiple tumor types, including breast, lung, and melanoma cancers.

The solutions allow users to conduct regulatory-grade studies in major cancers and accelerate time to insight on oncology data. It also enables researchers to develop evidence for synthetic control arm and label expansion studies, to fulfill post-marketing safety requirements, and to assess the economic impact of treatments.